Tags : Takeda

Viewpoints

ViewPoints Interview: Takeda’s Nirav Desai Shares Insight on Data of

In an interview with PharmaShots, Nirav Desai, Global Clinical Development Lead at Takeda shared his views on TAK-721 data presented at ACG 2020 and its implications for patients and HCPs. The presentation includes post hoc analyses from a 12-week, randomized, double-blind, placebo-controlled Phase 3 clinical trial that investigated the safety and efficacy of BOS in patients with EoE 11 […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Mar 22 – 26, 2021)

Pfizer and BioNTech Initiate COVID-19 Vaccine Trial in Children Under 12 Published: Mar 26, 2021 | Tags: Pfizer and BioNTech, Initiate, COVID-19 Vaccine Trial, Children, Under 12 Tetra Bio-Pharma Initiates Additional Studies of ARDS-003 in Neuroinflammation and Antiviral Diseases Published: Mar 26, 2021 | Tags: Tetra Bio-Pharma, Initiates, Additional Studies, ARDS-003,  Neuroinflammation, Antiviral Diseases Immunai […]Read More

Biotech

Takeda Collaborates with Evotec on RNA Targeting Drug Development

Shots: Evotec to receive research funding and will be eligible for $160M/program as discovery, pre/ clinical, a commercial milestone along with royalties on sales of product emerges from the collaboration The collaboration will utilize Evotec’s RNA targeting platform to identify RNA sequences to target with small-molecule ligands aligned that can be developed into the first-in-class […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Mar 15 – 19, 2021)

Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases Published: Mar 19, 2021 | Tags: Takeda, Collaborates, Anima, Discover, Develop, mRNA Translation Modulators, Neurological Diseases Kiniksa’s Arcalyst (rilonacept) Receives the US FDA’s Approval for the Treatment of Pericarditis Published: Mar 19, 2021 | Tags: Kiniksa, Arcalyst (rilonacept), Receives, US, FDA, […]Read More

Biotech

Takeda Signs a License Agreement with Genevant to Develop Novel

Shots: Genevant to receive up to $600M up front and milestone as well as royalties on future product sales Takeda get exclusive rights to access Genevant’s LNP technology for a specified number of selected hepatic stellate cells targets The companies collaborated to discover, develop and commercialize the LNP-delivered nucleic acid therapeutics directed to previously inaccessible […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Mar 08 – 12, 2021)

PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab Published: Mar 12, 2021 | Tags: PhaseBio, Signs, Supply, Agreement, BioVectra, Support,  Development, Commercialization, Bentracimab Takeda Reports NDA Submission of Lanadelumab to the MHLW as a Preventive Treatment for Hereditary Angioedema Attack in Japan Published: Mar 12, 2021 | Tags: […]Read More

Insights+

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012 The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available […]Read More